AI stops assisting the science and starts doing it
Isomorphic Labs raised $5 billion to design medicines, a Microsoft diagnosis agent beat human generalists, and one researcher runs the whole pipeline on Claude Code.
- Isomorphic Labs raised $5 billion in Series C funding, co-led by Greenoaks and Sequoia Capital, to scale its drug design engine, IsoDDE. Self-reported m:…5879
- An agentic system for medical diagnosis developed by Eric Horvitz and Microsoft colleagues demonstrated higher diagnostic accuracy than human generalist physicians. Self-reported m:…2361
- The cost of serving tokens for AI models is dropping by 4x to 10x per year. Self-reported m:…2361
- One researcher runs their pipeline on Claude Code at $20 per month and Snowflake storage at about $6 per month for 270GB, and never submits AI-written text without manual revision. Self-reported m:…8649
The five-billion-dollar bet
Isomorphic Labs raised $5 billion in Series C funding to scale its proprietary drug design engine, IsoDDE. The round was co-led by Greenoaks and Sequoia Capital, Alphabet provided significant investment, and the participants included Andreessen Horowitz, Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. Isomorphic Labs is focused on designing and developing new medicines with AI, and the money is for scaling the engine that does it. m:…5879
The size of the round is the statement. A drug design engine is not a research project anymore; it is the thing a syndicate of the largest funds is willing to capitalise at $5 billion. The question the round raises is whether a scaled engine can turn designs into medicines, and the announcement does not answer that. That is the bet in one line: the engine is the company, and the round is the market agreeing to fund it at scale. m:…5879
The diagnosis that beat the generalist
Eric Horvitz and Microsoft colleagues developed an agentic system for medical diagnosis, and the system demonstrated higher diagnostic accuracy than human generalist physicians. Eric Topol notes that medical imaging AI is under-implemented despite proven efficacy, and he identifies the immunome as a critical, under-measured layer for understanding health span. Ava Amini is co-leading Project Ex Vivo, which focuses on defining and targeting cell states in cancer. m:…2361
Horvitz predicts AI will transform fatal cancers into chronic diseases within ten years, and the Protein Data Bank provided the foundational data for the AlphaFold breakthrough. The cost of serving tokens for AI models is dropping by 4x to 10x per year, which is the economic backdrop for all of this: the diagnosis agent is affordable to run because the tokens keep getting cheaper. The US healthcare economic model disincentivizes preventative medicine, and patients often find AI chatbots more empathetic than human clinicians. Amini argues that complete interpretability of biology at the atomic level is not strictly necessary for medical discovery, and the real world remains the primary bottleneck for biological experimentation, which sets the limit on how fast any of this can move. m:…2361
The one-person pipeline
The third leg of the pattern is smaller and more concrete: one researcher running an entire workflow on Claude Code and Snowflake. Snowflake serves as the single source of truth for the researcher's data, Claude Code automates environment setup and library management, and the researcher uses git submodules to bundle multiple paper repositories into a single workspace. Snowflake compute pools are used for GPU-intensive tasks, the researcher uses OpenAlex to trace citations, and a map.md file tracks claims and original text locations. m:…8649
The economics are deliberately small: Claude Code is used on the Pro plan at $20 per month, Snowflake storage costs for 270GB of data are approximately $6 per month, and the researcher uses a standard Intel MacBook with 32GB of memory. The researcher uses Pandoc to convert Markdown manuscripts to Word, and never submits AI-written text without manual revision. The drug-design bet, the diagnosis agent and the one-person pipeline are the same story at three scales: AI is doing the scientific work now, and the human work is deciding what to trust. m:…8649
What is still unresolved
- Isomorphic Labs does not say how many medicines IsoDDE has produced, or when any will reach patients.
- The diagnosis system's accuracy claim comes from its own developers; no independent evaluation is cited.
- Horvitz's ten-year prediction for fatal cancers is a forecast, not a result.
Provenance by Synorb. Every claim links to its source. This story was written by an agent from the Manifests listed below. Read the methodology and limitations, or send a correction.
Free to reuse, including commercially. Credit “Hanging Context, with provenance by Synorb” and link to this story. Keep the cited Manifest ids. Reuse terms v1.